Abstract:Abstract Background Mutations in the DMD gene encoding dystrophin—a critical structural element in muscle cells—cause Duchenne muscular dystrophy (DMD), which is the most common fatal genetic disease. Clustered regularly interspaced short palindromic repeat (CRISPR)-mediated gene editing is a promising strategy for permanently curing DMD. Methods In this study, we developed a novel strategy for reframing DMD mutations via CRISPR-mediated large-scale excision of exons 46–54. We compared this approach with other DMD rescue strategies by using DMD patient-derived primary muscle-derived stem cells (DMD-MDSCs). Furthermore, a patient-derived xenograft (PDX) DMD mouse model was established by transplanting DMD-MDSCs into immunodeficient mice. CRISPR gene editing components were intramuscularly delivered into the mouse model by adeno-associated virus vectors. Results Results demonstrated that the large-scale excision of mutant DMD exons showed high efficiency in restoring dystrophin protein expression. We also confirmed that CRISPR from Prevotella and Francisella 1(Cas12a)-mediated genome editing could correct DMD mutation with the same efficiency as CRISPR-associated protein 9 (Cas9). In addition, more than 10% human DMD muscle fibers expressed dystrophin in the PDX DMD mouse model after treated by the large-scale excision strategies. The restored dystrophin in vivo was functional as demonstrated by the expression of the dystrophin glycoprotein complex member β-dystroglycan. Conclusions We demonstrated that the clinically relevant CRISPR/Cas9 could restore dystrophin in human muscle cells in vivo in the PDX DMD mouse model. This study demonstrated an approach for the application of gene therapy to other genetic diseases.

Fast, multiplexable and highly efficient somatic gene deletions in adult mouse skeletal muscle fibers using AAV-CRISPR/Cas9

Fast, multiplexable and efficient somatic gene deletions in adult mouse skeletal muscle fibers using AAV-CRISPR/Cas9

CASAAV: A CRISPR‐Based Platform for Rapid Dissection of Gene Function in Vivo

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

Efficient and multiplexed somatic genome editing with Cas12a mice

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9

In Vivo Gene Editing of Muscle Stem Cells with Adeno-Associated Viral Vectors in a Mouse Model of Duchenne Muscular Dystrophy

mRNA-mediated delivery of gene editing tools to human primary muscle stem cells

Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci

Tissue- and Time-Directed Electroporation of CAS9 Protein–grna Complexes in Vivo Yields Efficient Multigene Knockout for Studying Gene Function in Regeneration

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics

A Consolidated AAV System for Single-Cut CRISPR Correction of a Common Duchenne Muscular Dystrophy Mutation

Large genomic fragment deletion and functional gene cassette knock-in via Cas9 protein mediated genome editing in one-cell rodent embryos

Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

CRISPR/Cas9-mediated Gene Manipulation to Create Single-Amino-acid-substituted and Floxed Mice with a Cloning-Free Method

Efficient Gene Editing in Adult Mouse Livers Via Adenoviral Delivery of CRISPR/Cas9.